Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Promising new therapy for MS based on placenta cells.

A study published in the journal Multiple Sclerosis and Related Disorders, led by researchers at Mount Sinai in New York and Celgene Cellular Therapeutics revealed that an infusion based on cells derived from the placenta proved to be safe for patients with multiple sclerosis (MS) and a promising new therapy for the disease. The study is entitled “Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study.”

MS is a progressive neurodegenerative autoimmune disorder that results from an attack on the central nervous system (CNS) by the body’s own immune system, causing inflammation and damage to the myelin layer that covers and protects nerve fibers in the CNS. Myelin loss leads to impairment in signal transmission along the nerve fibers, affecting motor function (such as coordination, balance, speech and vision), causing irreversible neurological disability, paralysis and blindness. MS usually starts as an episodic disorder known as relapsing-remitting MS (RRMS), and in many patients it evolves into a more severe chronic condition with worsening disability named secondary progressive MS (SPMS). It is estimated that more than 2.3 million people in the world suffer from the disease.

Click to find out more about an SPMS clinical trial currently enrolling in Australia and New Zealand.

It has been previously shown that therapeutic cell-based infusions have an immunomodulatory and repair action in MS. PDA-001 in particular is a preparation of cultured mesenchymal-like cells derived from healthy human placental tissue and designed for the treatment of MS as these cells have immunomodulatory, anti-inflammatory, pro-regenerative and neuroprotective properties. As these placenta cells are expanded in cell culture, one healthy donor is capable of supplying enough cells for several patients.

In the study, researchers tested the safety and possible exacerbation of the disease with this new MS treatment approach based on PDA-001. A phase 1b, randomized, multicenter, double-blind, placebo-controlled study was conducted with 16 MS patients (10 with RRMS and 6 with SPMS), aged between 18 and 65 years. Six patients received a high dose of PDA-001 (600×106 cells), other six were given a lower dose (150×106 cells), and the remaining four patients received a placebo. Patients were monthly monitored for brain lesions through brain magnetic resonance imaging scans to assess possible disease progression.

Researchers found that none of the patients had worsening of MS-related brain lesions one year after treatment with both PDA-001 doses, and that in fact, the majority of the patients had stable or improved levels of disability.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels: ,

Go to Newer News Go to Older News